MoonLake Immunotherapeutics Receives Endorsement from FDA and EMA for Phase 3 Program of Sonelokimab in Treating Hidradenitis Suppurativa MoonLake Immunotherapeutics, an innovative biopharmaceutical company, has received the green light from key health authorities—the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)—for the advancement of their Phase 3 clinical tri..
BioCity Biopharma Completes Enrollment for IgA Nephropathy Patients in Phase II Trial of SC0062 Advancing Chronic Kidney Disease Treatment Overview Company: BioCity Biopharma Indication: Chronic kidney disease (CKD), IgA nephropathy (IgAN), diabetic kidney disease (DKD) Drug: SC0062 Trial Phase: Phase 2 NCT ID: N/A Background Headquartered in Wuxi, China, BioCity Biopharma is steadfast in its de..
Intrommune Therapeutics, Inc., a clinical stage biotechnology company, has successfully completed the final visit of the last patient in the Phase 1 OMEGA Clinical Study for individuals with peanut allergy. This 48-week trial is specifically designed for adults with peanut allergies and aims to gather long-term safety data while determining the appropriate starting dose for INT301, an innovative..
ke-size="size16">  With the implementation of CYBRA's RFID tracking solution, Thermo Fisher was able to ensure the integrity and safety of their serum inventory. The system provided real-time monitoring of temperature conditions, ensuring that the sub-zero temperatures required for storage were maintained at all times.   In addition to temperature monitoring, the RFID solution also enabl..
Rosalind Franklin University researcher, Dr. Grace E. Stutzmann, has been granted $1.8 million by the National Institute on Aging to investigate the connection between Down Syndrome and Alzheimer's disease. This research collaboration with New York University aims to develop new therapeutic strategies for individuals with Down Syndrome who are at risk of developing Alzheimer's. Down Syndrome is ..
Illumina, Inc. (NASDAQ: ILMN) and Pillar Biosciences Inc. have joined forces in a strategic partnership to expand the availability of Pillar's suite of oncology assays worldwide as part of Illumina's oncology product portfolio. The goal of this collaboration is to improve the efficiency, accuracy, and cost-effectiveness of oncology testing by utilizing advanced sequencing techniques, ultimately ..
OncoCyte, Corp. (Nasdaq: OCX), a precision diagnostics company, has recently released new data that demonstrates the effectiveness of VitaGraft Kidney in aiding physicians in treating kidney transplant patients with greater precision. The study focused on differentiating between two common causes of premature graft failure: antibody-mediated rejection (ABMR) and recurrent IgA nephropathy (IgAN)...
IntelGenx Corp. has recently announced a groundbreaking research collaboration with Karolinska University Hospital. The focus of this collaboration is to explore the potential of using Montelukast VersaFilm® as a treatment for Parkinson's Disease. Led by the esteemed Professor Per Svenningsson, an expert in clinical neuroscience, this study will delve into the efficacy of IntelGenx's innovative ..
Crescendo Biologics, a clinical stage immuno-oncology company, has secured an additional $32 million in funding. This capital infusion was made possible through the support of all major existing investors and new investor Kreos Capital. In conjunction with this exciting news, Crescendo has announced its plans to expand the Phase 1b trial of their lead program CB307 in PSMA+ solid tumors by intro..
